Syndax Pharmaceuticals Quarterly Income Statement
NASDAQ: SNDXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Syndax Pharmaceuticals revenue and earnings
In the quarter ended Jun 30, 2026, Syndax Pharmaceuticals generated $72.8 million in revenue, up 91.8% from the same quarter a year earlier. Syndax Pharmaceuticals reported a net loss of $49.4 million, compared with a loss of $71.8 million a year earlier. Operating margin was -54.9%.
Diluted earnings per share came in at -$0.55.
Summary generated from market data by MetaCap's automated system. Methodology
Syndax Pharmaceuticals income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 72.79M | 64.86M | 68.73M | 45.87M | 37.96M | 20.04M | 7.68M | 12.50M | 3.50M | 0 | 0 | 0 |
| Revenue growth (YoY) | +91.76% | +223.64% | +794.90% | +266.97% | +984.51% | — | — | — | — | — | — | — |
| Operating Expenses | 112.78M | 99.07M | 131.28M | 103.30M | 107.31M | 103.80M | 104.05M | 102.08M | 77.72M | 79.51M | 77.91M | 56.35M |
| Research & Development | 68.04M | 58.84M | 78.64M | 56.28M | 62.23M | 61.64M | 65.53M | 70.97M | 48.66M | 56.49M | 55.13M | 39.09M |
| Operating Income | -39.99M | -34.20M | -62.55M | -57.43M | -69.35M | -83.76M | -96.36M | -89.58M | -74.22M | -79.51M | -77.91M | -56.35M |
| Interest Expense | 2.00K | 0 | 0 | 0 | 4.00K | 2.00K | -124.00K | 23.00K | 45.00K | 55.00K | 63.00K | 70.00K |
| Other Income (Expense) | -9.37M | -8.47M | -5.47M | -3.29M | -2.49M | -1.09M | 2.20M | 5.45M | 6.15M | 7.11M | 5.43M | 5.21M |
| Income Tax | 0 | 0 | 433.00K | 0 | 0 | 0 | — | 0 | 0 | 0 | — | — |
| Net Income | -49.36M | -42.67M | -68.01M | -60.72M | -71.85M | -84.85M | -94.17M | -84.13M | -68.06M | -72.40M | -72.47M | -51.15M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| EPS (Basic) | -0.55 | -0.48 | -0.78 | -0.70 | -0.83 | -0.98 | -1.09 | -0.98 | -0.80 | -0.85 | -1.02 | -0.73 |
| EPS (Diluted) | -0.55 | -0.48 | -0.78 | -0.70 | -0.83 | -0.98 | -1.09 | -0.98 | -0.80 | -0.85 | -1.02 | -0.73 |
| Shares Outstanding (Basic) | 88.99M | 88.26M | — | 86.62M | 86.34M | 86.17M | — | 85.43M | 85.27M | 85.21M | — | 69.86M |
| Shares Outstanding (Diluted) | 88.99M | 88.26M | — | 86.62M | 86.34M | 86.17M | — | 85.43M | 85.27M | 85.21M | — | 69.86M |
| EBITDA | -34.99M | -30.20M | — | — | -69.35M | -83.76M | — | — | — | — | — | — |
| Operating Margin | -54.95% | -52.73% | -91.01% | -125.19% | -182.71% | -417.91% | -1254.75% | -716.62% | -2120.46% | — | — | — |
| Net Margin | -67.82% | -65.79% | -98.96% | -132.36% | -189.28% | -423.34% | -1226.16% | -673.01% | -1944.66% | — | — | — |
This table shows 12 quarterly periods of Syndax Pharmaceuticals's income statement, from Q2 2026 back to Q3 2023, across 15 line items including revenue, operating expenses, research & development. Values in USD; B = billions, M = millions. Fiscal periods follow SNDX's reporting calendar. What is a income statement?